GlassScriptPhysician profile
Kara Guisinger
NPI 1497285563
$2,083.79
in general payments reported to CMS, 2019-2025
13 companies · $595 in 2025
The $595 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.05 · 2022: $69.17 · 2023: $710 · 2024: $673 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,977.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $712.06 | 2022-2025 | Biktarvy |
| Viiv Healthcare Company | $686.85 | 2022-2025 | Apretude, Dovato, Cabenuva |
| Abbvie INC. | $330.57 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $126.01 | 2021-2025 | Pifeltro, Delstrigo |
| Theratechnologies INC. | $67.51 | 2023-2024 | Trogarzo, Egrifta |
| Emd Serono, INC. | $25.03 | 2025 | |
| Janssen Biotech, INC. | $23.31 | 2023 | Symtuza |
| Hologic Sales and Service, LLC | $21.97 | 2025 | Aptima, Thinprep 2000 Processor |
| Amarin Pharma, INC. | $21.20 | 2021 | |
| Verity Pharmaceuticals INC. | $19.32 | 2025 | Tlando |
| Antares Pharma, INC. | $18.81 | 2024 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.40 | 2025 | Caplyta |
| Exact Sciences Corporation | $12.75 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Guisinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.